Abstracts tagged "T cells and giant cell arteritis"

Abstract Number: 3042 • 2016 ACR/ARHP Annual Meeting
PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions
Ryu Watanabe¹, Hui Zhang², Ebru Hosgur², Gerald Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand², ¹Medicine: Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Pathology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: The vasculitic lesions in GCA are filled with differentiated effector T cells that sustain granuloma formation, vessel wall restructuring, neoangiogenesis and intimal hyperplasia. Persistent…
Abstract Number: 2849 • 2014 ACR/ARHP Annual Meeting
Involvement of CD8⁺ T Cells in the Pathogenesis of Giant Cell Arteritis and Polymyalgia Rheumatica
Maxime Samson¹, Sylvain Audia¹, Malika Trad², Marion Ciudad², Hervé Devilliers³, Alexandrine Gautheron², Valérie Quipourt⁴, Francois Maurier⁵, Nadine Meaux Ruault⁶, Patrick Manckoundia⁴, Paul Ornetti⁷, Jean-Francis Maillefert⁸, Jean-François Besancenot³, Christophe Ferrand⁹, Philippe Saas⁹, Laurent Martin¹⁰, Nona Janikashvili² and Bernard Bonnotte¹, ¹Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, ²University of Burgundy, Faculty of Medicine, IFR100, INSERM UMR 1098, Besançon, Dijon, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Dijon University Hospital, Department of Geriatric Internal Medicine, Dijon, France, ⁵HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁶Besançon University Hospital, Department of Internal Medicine, Besançon, France, ⁷Dijon University Hospital, Department of Rheumatology, Dijon, France, ⁸Rheumatology, University Hospital Dijon, Dijon, France, ⁹Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ¹⁰Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Pathology, Dijon, France
Background/Purpose Previous studies have demonstrated the implication of CD4+ T cells, especially T helper (Th1) and Th17 cells, in the pathogenesis of giant cell arteritis (GCA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].